You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

Article metrics

Article menu

Download PDFPDF

XML
Research Article
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

 

Online download statistics by month:

Online download statistics by month: December 2019 to March 2024

AbstractFullPdf
Dec 201911110
Jan 202087872
Feb 202081814
Mar 202038383
Apr 2020494913
May 2020373712
Jun 2020333315
Jul 2020323210
Aug 2020383811
Sep 2020727123
Oct 2020484823
Nov 2020616110
Dec 2020404012
Jan 2021797928
Feb 2021545414
Mar 2021898926
Apr 2021616114
May 2021696929
Jun 2021454518
Jul 202110410419
Aug 202131317
Sep 2021555524
Oct 2021515135
Nov 2021464530
Dec 2021525625
Jan 202236379
Feb 2022464721
Mar 2022566010
Apr 202269709
May 2022505020
Jun 202218189
Jul 2022383914
Aug 2022565715
Sep 2022383918
Oct 2022363716
Nov 2022414316
Dec 2022484810
Jan 2023495110
Feb 2023535420
Mar 202341499
Apr 2023272813
May 2023242410
Jun 2023343411
Jul 2023353522
Aug 2023252613
Sep 2023353910
Oct 2023303017
Nov 202319196
Dec 202326267
Jan 2024464710
Feb 202430309
Mar 2024252521
Total23942427762